Loading...
skip to Main Content
ligneverte

Discover the Scientific Programme

NAFLD-2022-programme-overview
View the full programme

Session 1: Epidemiology, disease modifiers, and models of care

  • Current epidemiology and future trends
  • Nutrition, alcohol, and environmental toxins as (co-) factors of NAFLD
  • Case finding, screening of risk populations, and clinical algorithms
  • Evolving models of care: How will the future look?
  • Panel discussion

Session 2: New technologies for better stratification of patients

  • Disease phenotyping by metabolomics and lipidomics
  • Are polygenic risk scores ready for clinical routine?
  • Machine learning approaches relating to NAFLD
  • Digital pathology and image analysis
  • Panel discussion

Session 3: Non-invasive fibrosis markers : Present and future

  • Serum-based biomarkers: Staging and treatment response
  • Imaging biomarkers: Staging and treatment response
  • Panel discussion: The future of liver biopsy

Session 4: Mechanisms of disease progression and implications for therapeutic targets

  • Advances in understanding intrinsic mechanisms in NAFLD: metabolism
  • Advances in understanding intrinsic mechanisms in NAFLD: inflammation, fibrosis
  • Organ cross-talk as a NAFLD modulator: gut and adipose tissue
  • Organ cross-talk as a NAFLD modulator: brain and endocrine signals
  • Panel discussion

Session 5: New approaches to lifestyle modification – case-based discussion

  • Case presentation
  • Short presentations from different disciplines:
    - Nutrition & app specialist
    - Exercise trainer
    - Bariatric surgeon
    - Hepatology
  • Panel discussion

Session 6: Personalized medicine in 2032 – how will it look like?

  • Sexual dimorphism: the overlooked obvious?
  • Gut microbiota as a target for personalized NAFLD interventions
  • Gene silencing by siRNA treatment
  • Biomarkers for personalized NAFLD medicine – thinking outside the box
  • Panel discussion

Session 7: Overlooked issues in clinical trials

  • Cardiovascular safety
  • Extrahepatic malignancies
  • Alcohol misuse, depression, anxiety
  • The patient’s perspective
  • Panel discussion

Session 8: How do pharmacological treatments of comorbidities affect NAFLD – case-based discussion

  • Case presentation
  • Short presentations from different disciplines:
    - Obesity
    - Dyslipidemia
    - Diabetes
    - Hypothyreoidism
  • Panel discussion

Session 9: Why do trials fail? Industry perspective & academia perspective 

  • Selonsertib
  • Cenicriviroc
  • Elafibranor
  • Panel discussion: Consequences for future trials?

Session 10: Clinical trial landscape in 2022

  • Phase 1-2 drug candidates for non-cirrhotic NASH
  • Phase 3 non-cirrhotic NASH
  • Cirrhotic NASH
  • Discussion
Back To Top